• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

    4/3/25 4:01:00 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    • Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025
    • Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohort
    • Strong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig

    ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the full year ended December 31, 2024, and highlighted recent pipeline progress and business updates.

    "The last year has been transformational for I-Mab. We successfully established a new model as a U.S.-based biotech company, divested all business operations in China, redefined our strategy, strengthened our leadership team, reprioritized our pipeline and accelerated the development of our lead program, givastomig, a novel Claudin-18.2 targeted therapy," said Sean Fu, PhD, MBA, CEO and board member of I-Mab. "We believe givastomig is uniquely situated to be a potential best-in-class, Claudin-18.2 therapy, with broad applicability in gastric cancer and beyond, and our strong cash balance positions us to build on the momentum."

    2024 Selected Finance and Corporate Development Highlights:

    • Appointment of Sean (Xi-Yong) Fu, PhD, MBA, as Chief Executive Officer.
    • Completed divestiture of Greater China assets and business operations, including settlement of all non-participating shareholder redemption obligations.

    Pipeline Overview and Potential Upcoming Milestones

    In January 2025, the Company announced a portfolio re-prioritization, with a focus on advancing its lead program, givastomig, a CLDN18.2 x 4-1BB bispecific antibody, targeting first-line (1L) metastatic gastric cancers, with further potential in other solid tumors. The Company continues to monitor development of uliledlimab, an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment, in Phase 2 studies with its partner, TJ Biopharma, and support ongoing studies underway with its partner, ABL Bio, for ragistomig, a bispecific, Fc-silent antibody designed to provide anti-PD-L1 activity and conditional 4-1BB-driven T-cell activation in one molecule.

    Givastomig

    Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting CLDN18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for 1L metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain a strong tumor-binding property and promising anti-tumor activity, attributable to a potential synergistic effect of proximal interaction between CLDN18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.

    Enrollment recently completed in the first dose expansion cohort (n=20), ahead of schedule, with continued momentum in the second dose expansion cohort (n=20). The Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy. The study builds on positive Phase 1 monotherapy data.

    Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.

    Upcoming Phase 1b Givastomig Milestones:

    • 2H 2025: Phase 1b dose escalation data (n=17) expected to be presented at a medical meeting.
    • 1H 2026: Expected topline results from the ongoing dose expansion study (n=40).

    Full Year 2024 Financial Results

    Cash Position

    As of December 31, 2024, the Company had cash, cash equivalents, and short-term investments of $173.4 million. The Company's current cash position is expected to fund the givastomig Phase 1b study through anticipated dose expansion data readouts and further development initiatives into 2027.

    Shares Outstanding

    As of December 31, 2024, the Company had 187,452,495 ordinary shares issued and outstanding, representing the equivalent of 81,501,085 ADSs, assuming the conversion of all ordinary shares into ADSs.

    Research & Development Expenses

    Research and development expenses were $21.8 million for the year ended December 31, 2024, compared to $21.4 million for the year ended December 31, 2023. The increase was primarily attributable to an increase in givastomig-related spending, partially offset by a decrease of $1.9 million in employee-related expenses due to lower headcount and a decline in stock price.

    Administrative Expenses

    Administrative expenses were $29.7 million for the year ended December 31, 2024, compared to $28.2 million for the year ended December 31, 2023. The increase was primarily attributable to an increase in professional services fees of $13.8 million due to an increase in legal expenses associated with certain trade secret misappropriation disputes against Inhibrx, Inc. This increase was partially offset by a decrease in employee-related expenses of $12.4 million due to the forfeiture of shares as a result of the divestiture of the Greater China assets and business operations and a decline in stock price, as well as exits of certain executive employees.

    Interest Income

    Interest income was $7.5 million for the year ended December 31, 2024, compared to $9.3 million for the year ended December 31, 2023. The decrease was primarily attributable to lower average investable cash balances.

    Other Expenses, Net

    Other expenses, net were $4.7 million for the year ended December 31, 2024, compared to $8.1 million for the year ended December 31, 2023. The change was primarily attributable to the fair value changes and extinguishment of put right liabilities and a smaller impact from foreign exchange losses, partially offset by expenses recognized on the settlement of non-participating shareholder redemption obligations and fixed asset impairments.

    Equity in Loss of Affiliates

    Equity in loss of affiliates was $1.0 million for the year ended December 31, 2024, compared to $11.4 million for the year ended December 31, 2023. The decrease was driven by no further recognition of allocated losses from our unconsolidated investee, as the investee no longer qualified for equity method accounting after the first quarter of 2023, and a decline in employee stock ownership plan expenses through the first quarter of 2024 prior to the transfer of our shares in the unconsolidated investee to certain participating shareholders in connection with the divestiture of the Greater China assets and business operations.

    Net Loss from Continuing Operations

    Net loss from continuing operations was $(49.7) million for the year ended December 31, 2024, compared to $(82.2) million for the year ended December 31, 2023. Net loss from continuing operations per share attributable to ordinary shareholders was $(0.27) for the year ended December 31, 2024 compared to $(0.43) for the year ended December 31, 2023.

    Net Loss from Discontinued Operations

    On April 2, 2024, the Company closed the China divestiture announced on February 7, 2024 (the "Transaction"). The Company determined that the Transaction represented a strategic shift that had a major effect on the business and therefore, met the criteria for classification as discontinued operations at December 31, 2024. Accordingly, the carrying value of in-process research and development and the net assets associated with the Greater China business operations are reported as discontinued operations in accordance with ASC 205-20, Discontinued Operations. Amounts applicable to prior years have been recast to conform to the discontinued operations presentation. The Company recognized a gain on the Transaction in the amount of $34.4 million for the year ended December 31, 2024, and a loss from operations of the discontinued component of $6.9 million for the year ended December 31, 2024.

    Net Loss

    Net loss was $(22.2) million for the year ended December 31, 2024, compared to $(207.7) million for the year ended December 31, 2023. Net loss per share attributable to ordinary shareholders was $(0.12) for the year ended December 31, 2024 compared to $(1.09) for the year ended December 31, 2023.

    About I-Mab

    I-Mab (NASDAQ:IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

    Exchange Rate Information

    As part of I-Mab's strategic transition to a U.S.-based biotech, effective April 2, 2024, the Company changed its reporting currency from RMB to USD. As indicated in its interim financial results, reported on August 28, 2024, the Company applied this change retrospectively to its historical results of operations and financial statements, as if the Company had always used the U.S. dollar as its reporting currency.  

    I-Mab Forward Looking Statements

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "believes", "designed to", "anticipates", "future", "intends", "plans", "potential", "estimates", "confident", and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company's pipeline and clinical development of I-Mab's drug candidates, including givastomig; the projected advancement of the Company's portfolio and anticipated milestones and related timing; the Company's expectations regarding the impact of data from ongoing and future clinical trials; the Company's expectations regarding its cash runway; the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the "Risk Factors" section in I-Mab's annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

    I-Mab Investor & Media Contacts

    PJ Kelleher 
    LifeSci Advisors 
    +1-617-430-7579 
    [email protected] 
    [email protected] 



     
    I-Mab
    Consolidated Balance Sheets
    (All amounts in thousands, except for share data)
     As of December 31, 
     2024  2023 
    Assets     
    Current assets     
    Cash and cash equivalents$68,263  $291,506 
    Short-term investments 105,135   20,221 
    Prepayments and other receivables 3,295   2,503 
    Current assets of discontinued operations —   15,682 
    Total current assets 176,693   329,912 
    Property, equipment and software 201   1,777 
    Operating lease right-of-use assets 3,597   3,777 
    Investments at fair value, available-for-sale debt securities (amortized cost of $38,727 and $0, respectively) 30,824   — 
    Other non-current assets 1,365   248 
    Non-current assets of discontinued operations —   33,208 
    Total assets$212,680  $368,922 
          
    Liabilities and shareholders' equity     
    Current liabilities     
    Accruals and other payables$7,638  $7,849 
    Operating lease liabilities, current 816   626 
    Current liabilities of discontinued operations —   49,669 
    Total current liabilities 8,454   58,144 
    Put right liabilities, non-current —   13,852 
    Operating lease liabilities, non-current 3,066   3,261 
    Other non-current liabilities —   106 
    Non-current liabilities of discontinued operations —   50,975 
    Total liabilities 11,520   126,338 
    Commitments and contingencies     
          
    Shareholders' equity     
    Ordinary shares ($0.0001 par value, 800,000,000 shares authorized as of

    December 31, 2024 and 2023; 187,452,495 and 185,613,662 shares issued and

    outstanding as of December 31, 2024 and 2023, respectively)
     19   19 
    Treasury stock (6,225)  (8,007)
    Additional paid-in capital 1,460,021   1,474,610 
    Accumulated other comprehensive income 33,384   39,771 
    Accumulated deficit (1,286,039)  (1,263,809)
    Total shareholders' equity 201,160   242,584 
    Total liabilities and shareholders' equity$212,680  $368,922 
     



    I-Mab
    Consolidated Statements of Comprehensive Loss
    (All amounts in thousands, except for share and per share data)
     Year Ended December 31, 
     2024  2023  2022 
    Revenues        
    Licensing and collaboration revenue$—  $632  $(1,551)
    Total revenues —   632   (1,551)
    Expenses        
    Research and development expenses(1) (21,770)  (21,448)  (22,547)
    Administrative expenses(2) (29,656)  (28,160)  (28,980)
    Impairment of goodwill —   (23,041)  — 
    Total expenses (51,426)  (72,649)  (51,527)
    Loss from operations (51,426)  (72,017)  (53,078)
    Interest income 7,486   9,294   4,954 
    Other expenses, net (4,718)  (8,090)  (28,269)
    Equity in loss of affiliates(3) (1,038)  (11,404)  (64,707)
    Loss from continuing operations before income tax expense (49,696)  (82,217)  (141,100)
    Income tax expense —   —   (103)
    Loss from continuing operations$(49,696) $(82,217) $(141,203)
             
    Discontinued operations:        
    Loss from operations of discontinued operations(4)$(6,898) $(125,512) $(229,850)
    Income tax expense —   —   — 
    Gain on sale of discontinued operations 34,364   —   — 
    Gain (loss) from discontinued operations$27,466  $(125,512) $(229,850)
             
    Net loss$(22,230) $(207,729) $(371,053)
             
    Other comprehensive income (loss):        
    Unrealized loss on available-for-sale debt securities, net of tax$(8,168) $—  $— 
    Foreign currency translation adjustments, net of tax 1,781   5,605   5,587 
    Total comprehensive loss$(28,617) $(202,124) $(365,466)
             
    Weighted-average number of ordinary shares used in calculating net

    loss per share - basic and diluted
     186,728,372   191,423,850   189,787,292 
    Net loss from continuing operations per share - basic and diluted$(0.27) $(0.43) $(0.74)
    Net gain (loss) from discontinued operations per share - basic and

    diluted
    $0.15  $(0.66) $(1.22)
    Net loss per share - basic and diluted$(0.12) $(1.09) $(1.96)
             
    Net loss from continuing operations per ADS(5)- basic and diluted$(0.61) $(0.99) $(1.71)
    Net gain (loss) from discontinued operations per ADS(5)- basic and

    diluted
    $0.34  $(1.51) $(2.79)
    Net loss per ADS(5)- basic and diluted$(0.27) $(2.50) $(4.50)
     

    (1) Includes share-based compensation expense of $1.6 million, $2.9 million and $3.5 million for the years ended December 31, 2024, 2023 and 2022, respectively.

    (2) Includes share-based compensation expense of $(3.5) million, $7.4 million and $9.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. The year ended December 31, 2024 includes forfeitures as a result of divestiture of the Greater China assets and business operations and organizational changes.

    (3) Includes share-based compensation expense of $(0.7) million, $0.7 million and $2.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. The year ended December 31, 2024 includes forfeitures as a result of divestiture of the Greater China assets and business operations.

    (4) Includes share-based compensation expense of $(11.6) million, $17.1 million and $39.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. The year ended December 31, 2024 includes forfeitures as a result of divestiture of the Greater China assets and business operations.

    (5) Each 10 ADSs represents 23 ordinary shares.

    I-Mab
    Consolidated Statements of Cash Flows
    (All amounts in thousands)
     Year Ended December 31, 
     2024  2023  2022 
    Cash flows from operating activities        
    Net loss$(22,230) $(207,729) $(371,053)
    Less: net gain (loss) from discontinued operations 27,466   (125,512)  (229,850)
    Net loss from continuing operations (49,696)  (82,217)  (141,203)
    Adjustments to reconcile net loss to net cash used in operating activities

    from continuing operations
            
    Share-based compensation (1,949)  10,239   13,149 
    Change in fair value and extinguishment of put right liabilities (13,852)  1,118   (5,070)
    Equity in loss of affiliates 1,038   11,404   64,707 
    Depreciation of property, equipment and software 261   475   206 
    Impairment of goodwill —   23,041   — 
    Settlement of TJ Biopharma repurchase obligations 12,388   —   — 
    Amortization of right-of use assets 717   586   1,209 
    Impairment of fixed assets 622   —   — 
    Impairment of assets held for sale 624   —   — 
    Gain on disposal of property and equipment (11)  —   (27)
    Change in fair value of short-term and other investments —   (221)  (1,898)
    Recognition of deferred cost for planned dual listing —   —   2,253 
    Changes in operating assets and liabilities        
    Prepayments and other receivables (1,904)  28   (1,800)
    Accruals and other payables (213)  (35,681)  18,337 
    Other non-current liabilities (106)  (894)  226 
    Operating lease liability, net (588)  (575)  (1,217)
    Accounts receivable —   —   (2,755)
    Contract assets —   —   4,301 
    Net cash used in operating activities from continuing operations (52,669)  (72,697)  (49,582)
    Cash flows from investing activities        
    Proceeds from disposal of short-term and other investments 109,834   85,000   764,421 
    Purchase of short-term and other investments (194,748)  (100,000)  (767,510)
    Purchase of available-for-sale debt securities (51,115)  —   — 
    Purchase of property, equipment and software (48)  (164)  (2,091)
    Proceeds from disposal of property and equipment 62   —   — 
    Net cash used in investing activities from continuing operations (136,015)  (15,164)  (5,180)
    Cash flows from financing activities        
    Payment for stock repurchases (335)  (8,644)  (3,006)
    Proceeds from exercise of stock options —   407   6,918 
    Net cash (used in) generated from financing activities from continuing

    operations
    $(335) $(8,237) $3,912 
     



    I-Mab
    Consolidated Statements of Cash Flows (continued)
    (All amounts in thousands)
     Year Ended December 31, 
     2024  2023  2022 
    Discontinued operations:        
    Net cash used in operating activities$(27,498) $(109,791) $(116,663)
    Net cash (used in) generated from investing activities (22,289)  26,077   73,216 
    Net cash (used in) generated from financing activities (4,171)  9,911   2,805 
    Net cash used in discontinued operations (53,958)  (73,803)  (40,642)
    Effect of exchange rate changes on cash, cash equivalents and restricted

    cash
     573   5,197   14,197 
    Net decrease in cash and cash equivalents (242,404)  (164,704)  (77,295)
             
    Cash and cash equivalents, beginning of year 310,667   475,371   552,666 
    Cash and cash equivalents, end of year$68,263  $310,667  $475,371 
             
    Additional ASC 842 supplemental disclosures        
    Cash paid for fixed operating lease costs included in the measurement

    of lease obligations in operating activities
    $805  $739  $909 
    Right-of-use assets obtained in exchange for operating lease obligations$282  $1,426  $— 
    Other supplemental cash flow disclosures        
    Income tax paid$—  $—  $103 
    Interest paid$—  $—  $— 
    Non-cash activities        
    Payables for purchase of property, equipment and software$—  $—  $124 
    Unrealized loss on available-for-sale debt securities$8,168  $—  $— 
             
    The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated Balance Sheets: 
    Cash and cash equivalents$68,263  $291,506  $342,922 
    Restricted cash(1) —   —   5,000 
    Cash and cash equivalents in current assets of discontinued operations —   10,843   8,894 
    Restricted cash in non-current assets of discontinued operations —   8,318   118,555 
    Total cash and cash equivalents and restricted cash$68,263  $310,667  $475,371 
     

    (1)   The $5.0 million of restricted cash represents cash deposits placed by I-Mab Hong Kong in connection with a December 2022 bank loan held by TJBio Shanghai. This borrowing was repaid in full and the restrictions on the cash deposits were released during 2023.



    Primary Logo

    Get the next $IMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

      ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for a combination study of givastomig plus nivolumab and chemotherapy has been accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, which will be held July 2-5 in Barcelona, Spain. "We are very pleased to receive confirmation that new clinical data for givastomig has been accepted as an oral presentation at the upcoming ESMO Gastrointestinal Cancers Congress 2025. As more information becomes available fr

      4/30/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

      Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

      4/3/25 4:01:00 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

      ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025. Details are as follows: 24th Annual Needham Virtual Healthcare Conference Conference Date:April 7-10, 2025Format:Company Presentation and one-on-one meetingsPresentation Time:Monday, April 7, 2025, 8:45 to 9:25 AM ETWebcast Link:Register here   About I-Mab I-Mab (NASDAQ:IMAB) is a US-based, global biotech company, focused on the developm

      3/26/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Financials

    Live finance-specific insights

    See more
    • I-Mab to Release Q3 2024 Financial Results on November 14, 2024

      ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

      10/31/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

      Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

      8/28/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Release 1H 2024 Financial Results on August 28, 2024

      Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

      8/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by I-MAB (Amendment)

      SC 13G/A - I-Mab (0001778016) (Subject)

      2/13/24 11:26:50 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by I-MAB (Amendment)

      SC 13G/A - I-Mab (0001778016) (Subject)

      2/9/24 4:01:20 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by I-MAB

      SC 13D - I-Mab (0001778016) (Subject)

      12/1/23 2:41:06 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    SEC Filings

    See more
    • SEC Form F-3 filed by I-MAB

      F-3 - I-Mab (0001778016) (Filer)

      5/2/25 5:01:56 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      4/30/25 7:14:42 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      4/4/25 4:59:51 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Leadership Updates

    Live Leadership Updates

    See more

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

      Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

      4/3/25 4:01:00 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

      Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

      1/6/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports Third Quarter 2024 Results

      Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

      11/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Siebert Williams Shank initiated coverage on I-Mab with a new price target

      Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

      12/9/21 8:33:47 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on I-MAB with a new price target

      Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

      11/1/21 4:39:06 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

      HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

      9/1/21 6:14:32 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care